COVID-19 pneumonia. Confirmed diagnosis of COVID-19
Conditions
Interventions
Intervention 1: Intervention group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the herbal compound three times a day after meals. The herbal caps
Sponsors
HomaPharmed Company
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients infected with symptomatic covid-19 pneumonia virus Confirmation of coronavirus infection with chest CT scan and PCR test Age 20 to 70 years who have the ability to take oral medication Personal desire to participate in the project and the signing of a written consent
Exclusion criteria
Exclusion criteria: Patients with severe dyspnea Patients with reduced level of consciousness or need hospitalization in intensive care units Patients with swallowing disorders or possibility of aspiration of food or unable to take the drug orally Patients with respiratory failure require mechanical ventilation Patients with resistant hypoxemia Patients with organ transplantation; malignant disease; treated with corticosteroids or chemotherapy Patients with uncontrolled blood pressure, uncontrolled diabetes, cardiovascular disease and underlying respiratory disease Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood oxygen saturation. Timepoint: At beginning and regularly during study. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: At beginning and regularly during study. Method of measurement: Respiratory Count.;Lung inflammation. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan. | — |
Secondary
| Measure | Time frame |
|---|---|
| C-reactive protein. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;CBC. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;ESR. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;BUN. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Creatinine. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;K. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Na. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;Cough. Timepoint: At beginning and regularly during the study. Method of measurement: Count.;Fever. Timepoint: At beginning and regularly during the study. Method of measurement: Termometer.;ALT. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;AST. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test.;ALK. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFallah Huseini Hasan
Institute of Medicinal Plants
Outcome results
None listed